Clinical Trial Update: Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for Sym004 in squamous cell carcinoma of the head and neck after anti-EGFR therapy failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Sym004

Snippet

Sponsor: Symphogen A/S | Conditions: Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2016-02-02